th-302 and Squamous-Cell-Carcinoma-of-Head-and-Neck

th-302 has been researched along with Squamous-Cell-Carcinoma-of-Head-and-Neck* in 4 studies

Trials

1 trial(s) available for th-302 and Squamous-Cell-Carcinoma-of-Head-and-Neck

ArticleYear
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
    JCI insight, 2018, 08-23, Volume: 3, Issue:16

    Evofosfamide (TH-302) is a clinical-stage hypoxia-activated prodrug of a DNA-crosslinking nitrogen mustard that has potential utility for human papillomavirus (HPV) negative head and neck squamous cell carcinoma (HNSCC), in which tumor hypoxia limits treatment outcome. We report the preclinical efficacy, target engagement, preliminary predictive biomarkers and initial clinical activity of evofosfamide for HPV-negative HNSCC. Evofosfamide was assessed in 22 genomically characterized cell lines and 7 cell line-derived xenograft (CDX), patient-derived xenograft (PDX), orthotopic, and syngeneic tumor models. Biomarker analysis used RNA sequencing, whole-exome sequencing, and whole-genome CRISPR knockout screens. Five advanced/metastatic HNSCC patients received evofosfamide monotherapy (480 mg/m2 qw × 3 each month) in a phase 2 study. Evofosfamide was potent and highly selective for hypoxic HNSCC cells. Proliferative rate was a predominant evofosfamide sensitivity determinant and a proliferation metagene correlated with activity in CDX models. Evofosfamide showed efficacy as monotherapy and with radiotherapy in PDX models, augmented CTLA-4 blockade in syngeneic tumors, and reduced hypoxia in nodes disseminated from an orthotopic model. Of 5 advanced HNSCC patients treated with evofosfamide, 2 showed partial responses while 3 had stable disease. In conclusion, evofosfamide shows promising efficacy in aggressive HPV-negative HNSCC, with predictive biomarkers in development to support further clinical evaluation in this indication.

    Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Chemoradiotherapy; Drug Resistance, Neoplasm; Exome Sequencing; Female; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Middle Aged; Nitroimidazoles; Papillomaviridae; Phosphoramide Mustards; Prodrugs; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays; Young Adult

2018

Other Studies

3 other study(ies) available for th-302 and Squamous-Cell-Carcinoma-of-Head-and-Neck

ArticleYear
Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma.
    JCI insight, 2023, 02-22, Volume: 8, Issue:4

    Topics: Carcinoma, Squamous Cell; Head and Neck Neoplasms; Human Papillomavirus Viruses; Humans; Squamous Cell Carcinoma of Head and Neck

2023
Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019, Volume: 141

    Esophageal cancer incidence is increasing and is rarely curable. Hypoxic tumor areas cause resistance to conventional therapies, making them susceptible for treatment with hypoxia-activated prodrugs (HAPs). We investigated in vivo whether the HAP evofosfamide (TH-302) could increase the therapeutic ratio by sensitizing esophageal carcinomas to radiotherapy without increasing normal tissue toxicity.. To assess therapeutic efficacy, growth of xenografted esophageal squamous cell (OE21) or adeno (OE19) carcinomas was monitored after treatment with TH-302 (50 mg/kg, QD5) and irradiation (sham or 10 Gy). Short- and long-term toxicity was assessed in a gut mucosa and lung fibrosis irradiation model, sensitive to acute and late radiation injury respectively. Mice were injected with TH-302 (50 mg/kg, QD5) and the abdominal area (sham, 8 or 10 Gy) or the upper part of the right lung (sham, 20 Gy) was irradiated. Damage to normal tissues was assessed 84 hours later by histology and blood plasma citrulline levels (gut) and for up to 1 year by non-invasive micro CT imaging (lung).. The combination treatment of TH-302 with radiotherapy resulted in significant tumor growth delay in OE19 (P = 0.02) and OE21 (P = 0.03) carcinomas, compared to radiotherapy only. Irradiation resulted in a dose-dependent decrease of crypt survival (P < 0.001), mucosal surface area (P < 0.01) and citrulline levels (P < 0.001) in both tumor and non-tumor bearing animals. On the long-term, irradiation increased CT density in the lung, indicating fibrosis, over time. TH-302 did not influence the radiation-induced short-term and long-term toxicity, confirmed by histological evaluation.. The combination of TH-302 and radiotherapy might be a promising approach to improve the therapeutic index for esophageal cancer patients.

    Topics: Adenocarcinoma; Animals; Cell Line, Tumor; Esophageal Neoplasms; Female; Humans; Male; Mice; Nitroimidazoles; Phosphoramide Mustards; Radiation-Sensitizing Agents; Squamous Cell Carcinoma of Head and Neck

2019
Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models.
    Cells, 2019, 07-13, Volume: 8, Issue:7

    Tumour hypoxia is a marker of poor prognosis and failure of chemoradiotherapy in head and neck squamous cell carcinoma (HNSCC), providing a strategy for therapeutic intervention in this setting. To evaluate the utility of the hypoxia-activated prodrug evofosfamide (TH-302) in HNSCC, we established ten early passage patient-derived xenograft (PDX) models of HNSCC that were characterised by their histopathology, hypoxia status, gene expression, and sensitivity to evofosfamide. All PDX models closely resembled the histology of the patient tumours they were derived from. Pimonidazole-positive tumour hypoxic fractions ranged from 1.7-7.9% in line with reported HNSCC clinical values, while mRNA expression of the Toustrup hypoxia gene signature showed close correlations between PDX and matched patient tumours, together suggesting the PDX models may accurately model clinical tumour hypoxia. Evofosfamide as a single agent (50 mg/kg IP, qd × 5 for three weeks) demonstrated antitumour efficacy that was variable across the PDX models, ranging from complete regressions in one p16-positive PDX model to lack of significant activity in the three most resistant models. Despite all PDX models showing evidence of tumour hypoxia, and hypoxia being essential for activation of evofosfamide, the antitumour activity of evofosfamide only weakly correlated with tumour hypoxia status determined by pimonidazole immunohistochemistry. Other candidate evofosfamide sensitivity genes-

    Topics: Animals; Cytochrome P-450 Enzyme System; Head and Neck Neoplasms; Humans; Ki-67 Antigen; Mice; Mice, Inbred NOD; Nitroimidazoles; Nuclear Proteins; Phosphoramide Mustards; Squamous Cell Carcinoma of Head and Neck; Tumor Hypoxia; Xenograft Model Antitumor Assays

2019